Liopa, the automated lip reading company, has boosted its executive team with the appointment of Prof Potamianos as Technical Strategy Advisor
7th October, 2019, Belfast, UK: Liopa is excited to announce that Professor Gerasimos Potamianos has joined Liopa as Technical Strategy Advisor. Prof Potamianos, who is based at the University of Thessaly, Volos, Greece, will contribute to the direction of Liopa’s Visual Speech Recognition (VSR) technology – LipRead.
LipRead takes, as input, video of a subject(s) speaking. It uses advanced AI-Based techniques to decipher speech from analysis of speaker lip movements – essentially automated Lip Reading.
Liopa Founder & CEO Liam McQuillan said, “We are delighted Gerasimos is joining the team. He is a globally acclaimed authority in Speech recognition, having been heavily involved in commercial and academic research in the fields of Audio & Visual speech recognition for over 20 years.”
“This is an exciting moment to join as an advisor, in Liopa’s next stage of growth,” commented Prof Potamianos. “I am looking forward to working with Liopa’s management team on the development of a technical roadmap for the evolution of the LipRead VSR technology.”
ABOUT LIOPA
The company was spun out of the Centre for Secure Information Technologies (CSIT) at Queen’s University Belfast (QUB) in 2015. Since then Liopa has been onward developing and commercialising research carried out within the university into the use of Lip Movements (visemes) in Speech Recognition. The company is leveraging QUB’s renowned excellence in the area of speech, speaker and dialogue modelling to position Liopa as a leading independent provider of viseme-based VSR technology.
Contact:
Gillian@liopa.co.uk
+44(0)787 023 7688
info@liopa.ai
Source: RealWire
NEWARK, DE / ACCESSWIRE / November 22, 2024 / Laurel Bridge Software, a leader in…
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or…
Hemogenyx Pharmaceuticals plc("Hemogenyx Pharmaceuticals" or the "Company")Notice of Extraordinary General MeetingProposed Capital Reorganisation and New…
Diarrhea is one of the most common reasons for veterinary visits for dogs and the…
Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers…
FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the…